Soren Acquisition Corp.SORN

The most interesting thing about Soren Acquisition Corp. isn’t the mammography tech it’s supposedly commercialising-it’s the fact that, in the three months to 31 March 2026, the company turned a $1.7 million net profit while still haemorrhaging $527 k in operating cash. That’s less a business and more a filing exercise with a side of shareholder theatre. The company’s balance sheet shows $257.3 million in assets versus $297 k in liabilities, which sounds healthy until you realise the $2 million in stockholders’ equity is roughly the price of a single luxury flat in Mayfair and smaller than the average NHS trust deficit.

QT Imaging’s Breast Acoustic CT™ scanner sounds like a device beamed in from the future: non-ionising, non-compressive, and proudly displayed on the company’s website with the kind of glossy product photography usually reserved for smartphones. QT’s press office proudly announced $6.5 million in revenue for Q1 2026, yet Soren’s own filings don’t reconcile this figure to any line item in its accounts. Either the revenue is being booked outside the shell, or the company is counting future sales before the first lease is signed. The technology overview promises a “new era in breast imaging,” but the era so far appears to be one of PowerPoint slide decks rather than patient scans.

Soren’s most recent SEC filings include an 8-K dated 26 February 2026 announcing the “commencing” commercial launch of the QT Breast Acoustic CT™ scanner the following day. The same filing is silent on how many units were actually shipped or billed. QT Imaging’s own press releases, meanwhile, report Q1 2026 revenue of $6.5 million, which is a figure Soren’s 10-Q does not echo. Diluted EPS for the year to 31 December 2025 was a polite $-0.01, and the weighted average shares outstanding have swollen to 7.3 million, which is the kind of dilution that tends to delight lawyers and haunt retail holders. The board’s five separate 13G filings in May 2026 read less like shareholder updates and more like an exercise in ticking boxes.

Where to look next: Watch for any 8-K or 10-Q line item that references units shipped or revenue recognised from the QT scanner. Check QT Imaging’s press releases for any quarterly revenue reconciling to Soren’s reported figures. Track the next 13G filing to see if any director discloses an intention beyond passive ownership. Until then, the balance sheet’s quiet dignity remains the only asset with a verifiable balance.

The SEC EDGAR index for Soren lists 31 filings since inception, yet the company’s business model still reads like a shell with a shiny brochure. QT Imaging’s product pages showcase a sleek scanner and a promise of “non-ionising, non-compressive” imaging, but the only clinical outcome files attached are marketing collateral. The gap between the polished platform story and the actual cash collected remains wider than a mammography gantry.

Soren’s operating loss of $303 k in Q1 2026 and operating cash burn of $527 k tell a clearer story than any slide deck. The board’s 13G filings read like a who’s-who of passive investors keeping the lights on, while the actual imaging tech remains a prototype in search of a market. Until the cash register starts ringing in earnest, the company’s balance sheet is the only thing that behaves like an acquisition-and it’s still waiting to be acquired.